Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma
Public ClinicalTrials.gov record NCT00687687. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To estimate the antitumor activity of paclitaxel, carboplatin, plus BSI-201 in patients with recurrent or advanced uterine carcinosarcomas. Based on data generated by BiPar/Sanofi, it is concluded that iniparib does not possess characteristics typical of the PARP inhibitor class. The exact mechanism has not yet been fully elucidated, however based on experiments on tumor cells performed in the laboratory, iniparib is a novel investigational anti-cancer agent that induces gamma-H2AX (a marker of DNA damage) in tumor cell lines, induces cell cycle arrest in the G2/M phase in tumor cell lines, and potentiates the cell cycle effects of DNA damaging modalities in tumor cell lines. Investigations into potential targets of iniparib and its metabolites are ongoing.
Study identification
- NCT ID
- NCT00687687
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 22 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2008 (Type not available)
- Primary completion
- Mar 2010 (Actual)
- Completion
- Dec 2011 (Actual)
- Last update posted
- Aug 7, 2012
2008 – 2011
United States locations
- U.S. sites
- 40
- U.S. states
- 20
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Aurora | Colorado | — | — |
| Research Site | Englewood | Colorado | — | — |
| Research Site | New Britain | Connecticut | — | — |
| Research Site | Orlando | Florida | 32804 | — |
| Research Site | Gainsville | Georgia | — | — |
| Research Site | Savannah | Georgia | — | — |
| Research Site | Chicago | Illinois | 60612 | — |
| Research Site | Chicago | Illinois | — | — |
| Research Site | Hinsdale | Illinois | — | — |
| Research Site | Urbana | Illinois | — | — |
| Research Site | Indianapolis | Indiana | 46260 | — |
| Research Site | Baton Rouge | Louisiana | 70806 | — |
| Research Site | Scarborough | Maine | — | — |
| Research Site | Kalamazoo | Michigan | — | — |
| Research Site | Springfield | Missouri | 65804 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Camden | New Jersey | 08103 | — |
| Research Site | Brooklyn | New York | — | — |
| Research Site | Buffalo | New York | — | — |
| Research Site | New York | New York | — | — |
| Research Site | Stony Brook | New York | — | — |
| Research Site | Chapel Hill | North Carolina | — | — |
| Research Site | Charlotte | North Carolina | 28204 | — |
| Research Site | Charlotte | North Carolina | — | — |
| Research Site | Winston-Salem | North Carolina | 27157 | — |
| Research Site | Cleveland | Ohio | — | — |
| Research Site | Columbus | Ohio | 43235 | — |
| Research Site | Columbus | Ohio | — | — |
| Research Site | Mentor | Ohio | — | — |
| Research Site | Oklahoma City | Oklahoma | 73104 | — |
| Research Site | Tulsa | Oklahoma | — | — |
| Research Site | Abington | Pennsylvania | — | — |
| Research Site | Pittsburgh | Pennsylvania | — | — |
| Research Site | Wynnewood | Pennsylvania | — | — |
| Research Site | Wyomissing | Pennsylvania | — | — |
| Research Site | Providence | Rhode Island | 02905 | — |
| Research Site | Burlington | Vermont | 05401 | — |
| Research Site | Richmond | Virginia | 23298 | — |
| Research Site | Roanoke | Virginia | 24014 | — |
| Research Site | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00687687, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 7, 2012 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00687687 live on ClinicalTrials.gov.